{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T23:03:26Z","timestamp":1777158206179,"version":"3.51.4"},"reference-count":79,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Diabetes mellitus (DM) is a major risk factor for cardiovascular disease, including heart failure (HF). A high proportion of DM patients eventually require cardiac surgery. While the traditional approach to DM therapy focuses on tight glucose control with insulin and oral hypoglycemic agents, novel antidiabetic drugs have emerged over the past two decades that offer not only improved glycemic control but also cardiovascular and renal protection, such as benefits in HF management. The aim of this review is to examine and evaluate the perioperative risk and benefits of novel antidiabetic agents in HF treatment for both DM and non-DM patients undergoing cardiac surgery. We specifically studied glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium\u2013glucose cotransporter 2 inhibitors (SGLT2is). Although studies on novel antidiabetic therapy in cardiac surgeries were limited, the results showed all three agents to be safe for use in the perioperative period, with SLGT2i demonstrating the most benefits in HF management for those with or without DM and kidney impairment undergoing cardiac surgery. Future research on larger study populations and using a more rigorous study design is necessary in bridging current knowledge to improve patient outcomes.<\/jats:p>","DOI":"10.3390\/life15030427","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:46:41Z","timestamp":1741596401000},"page":"427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-5778","authenticated-orcid":false,"given":"Ashley","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savannah","family":"Bitzas","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1704-4765","authenticated-orcid":false,"given":"Dilsa","family":"Perez","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleem","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Oster","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-5908","authenticated-orcid":false,"given":"Sergio D.","family":"Bergese","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"154838","DOI":"10.1016\/j.metabol.2021.154838","article-title":"Current Trends in Epidemiology of Cardiovascular Disease and Cardiovascular Risk Management in Type 2 Diabetes","volume":"123","author":"Yun","year":"2021","journal-title":"Metabolism"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement from the American Heart Association and the Heart Failure Society of America","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"ref_3","first-page":"e51151","article-title":"Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond","volume":"15","author":"Olanrewaju","year":"2023","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2337\/dc15-1817","article-title":"Diabetes and the Association of Postoperative Hyperglycemia with Clinical and Economic Outcomes in Cardiac Surgery","volume":"39","author":"Greco","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.athoracsur.2008.11.011","article-title":"The Society of Thoracic Surgeons Practice Guideline Series: Blood Glucose Management During Adult Cardiac Surgery","volume":"87","author":"Lazar","year":"2009","journal-title":"The Annals of Thoracic Surgery"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtcvs.2019.04.039","article-title":"Global cardiac surgery: Access to cardiac surgical care around the world","volume":"159","author":"Vervoort","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ejcts.2009.11.042","article-title":"Diabetes and Survival after Coronary Artery Bypass Grafting: Comparison with an Age- and Sex-Matched Population","volume":"37","author":"Martens","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"II-41","DOI":"10.1161\/01.CIR.0000138197.07051.e7","article-title":"Effect of Diabetes and Associated Conditions on Long-Term Survival after Coronary Artery Bypass Graft Surgery","volume":"110","author":"Leavitt","year":"2004","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/01.CIR.96.8.2551","article-title":"Relationship between Diabetes Mellitus and Long-Term Survival after Coronary Bypass and Angioplasty","volume":"96","author":"Barsness","year":"1997","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5935\/1678-9741.20160002","article-title":"Prognosis and Complications of Diabetic Patients Undergoing Isolated Coronary Artery Bypass Surgery","volume":"31","author":"Santos","year":"2015","journal-title":"Braz. J. Cardiovasc. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jtcvs.2018.02.011","article-title":"Heart failure with preserved ejection fraction as an independent risk factor of mortality after cardiothoracic surgery","volume":"156","author":"Nguyen","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e008902","DOI":"10.1161\/JAHA.118.008902","article-title":"Prevalence and Long-Term Survival after Coronary Artery Bypass Grafting in Women and Men with Heart Failure and Preserved versus Reduced Ejection Fraction","volume":"7","author":"Sun","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like Peptide-1: New Regulator in Lipid Metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"ref_15","unstructured":"Collins, L., and Costello, R.A. (2024, November 16). Glucagon-like Peptide-1 Receptor Agonists. StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like Peptide-1 Receptor: Mechanisms and Advances in Therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2018). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142019. Diabetes Care, 42, S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"key":"ref_18","first-page":"e45487","article-title":"Role of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients with Type 2 Diabetes Mellitus: A Systematic Review","volume":"15","author":"Parab","year":"2023","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and Renal Outcomes of Glucagon-like Peptide 1 Receptor Agonists among Patients with and without Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like Peptide 1 Receptor Agonists and Heart Failure","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"ref_21","unstructured":"Joshi, G., Abdelmalak, B., Weigel, W., Soriano, S., Harbell, M., Kuo, C., Stricker, P., and Domino, K. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, American Society of Anesthesiologists (ASA). Available online: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative."},{"key":"ref_22","unstructured":"(2024). Most Patients Can Continue Diabetes, Weight Loss GLP-1 Drugs Before Surgery, Those at Highest Risk for GI Problems Should Follow Liquid Diet Before Procedure, American Society of Anesthesiologists (ASA). Available online: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2024\/10\/new-multi-society-glp-1-guidance."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/bjaceaccp\/mkt053","article-title":"Aspiration under Anaesthesia: Risk Assessment and Decision-Making","volume":"14","author":"Robinson","year":"2014","journal-title":"Contin. Educ. Anaesth. Crit. Care Pain"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ahr\u00e9n, B. (2019). DPP-4 Inhibition and the Path to Clinical Proof. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00376"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"F661","DOI":"10.1152\/ajprenal.00316.2016","article-title":"Diabetes, Hypertension, and Chronic Kidney Disease Progression: Role of DPP-4","volume":"312","author":"Nistala","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"806979","DOI":"10.1155\/2015\/806979","article-title":"The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A \u201cMe Too\u201d or \u201cthe Special One\u201d Antidiabetic Class?","volume":"2015","author":"Godinho","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gilbert, M.P., and Pratley, R.E. (2020). GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00178"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/dmrr.2482","article-title":"Head-to-Head Comparison of Dipeptidyl Peptidase-IV Inhibitors and Sulfonylureas\u2014A Meta-Analysis from Randomized Clinical Trials","volume":"30","author":"Zhang","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bja.2023.02.039","article-title":"Current Practice in the Perioperative Management of Patients with Diabetes Mellitus: A Narrative Review","volume":"131","author":"Crowley","year":"2023","journal-title":"Br. J. Anaesth."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17446651.2023.2272865","article-title":"Preoperative Considerations for Patients with Diabetes","volume":"18","author":"Kirk","year":"2023","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: Physiology and Pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.17925\/HI.2023.17.2.5","article-title":"Sodium glucose Co-Transporter 2 inhibitors and the cardiovascular System: Current knowledge and future expectations","volume":"17","author":"Boutsikos","year":"2023","journal-title":"Heart Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: A review","volume":"21","author":"Ehrenkranz","year":"2004","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chan, J.C.H., and Chan, M.C.Y. (2023). SGLT2 inhibitors: The next blockbuster multifaceted drug?. Medicina, 59.","DOI":"10.3390\/medicina59020388"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_38","unstructured":"(2024, November 15). Story of Discovery: SGLT2 Inhibitors: Harnessing the Kidneys to Help Treat Diabetes; National Institute of Diabetes and Digestive and Kidney Diseases: 2020, Available online: https:\/\/www.niddk.nih.gov\/news\/archive\/2016\/story-discovery-sglt2-inhibitors-harnessing-kidneys-help-treat-diabetes#:~:text=The%20first%20SGLT2%20inhibitor%20to,Jardiance%C2%AE)%20in%20August%202014."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S125\u2013S143.","DOI":"10.2337\/dc22-S009"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of Sodium\u2013Glucose Co-Transporter Type 2 (SGLT2) inhibitors for the treatment of Type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2014","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1053\/j.jvca.2022.02.019","article-title":"SGLT-2 inhibitors: Proliferating indications and perioperative pitfalls","volume":"36","author":"Madhok","year":"2022","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e36895","DOI":"10.1097\/MD.0000000000036895","article-title":"A comprehensive review of heart failure: Unraveling the etiology, decoding pathophysiological mechanisms, navigating diagnostic modalities, exploring pharmacological interventions, advocating lifestyle modifications, and charting the horizon of emerging therapies in the complex landscape of chronic cardiac dysfunction","volume":"103","author":"Elendu","year":"2024","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1152\/physiolgenomics.00100.2007","article-title":"Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling","volume":"35","author":"Gao","year":"2008","journal-title":"Physiol. Genom."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jama.2020.13310","article-title":"Heart failure","volume":"324","author":"Baman","year":"2020","journal-title":"JAMA"},{"key":"ref_49","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Reina-Couto, M., Pereira-Terra, P., Quelhas-Santos, J., Silva-Pereira, C., Albino-Teixeira, A., and Sousa, T. (2021). Inflammation in human heart failure: Major mediators and therapeutic targets. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.746494"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-022-00972-6","article-title":"Signaling cascades in the failing heart and emerging therapeutic strategies","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like Peptide 1 Receptor Agonists in Patients with Type 2 Diabetes with and without Chronic Heart Failure: A Meta-Analysis of Randomized Placebo-Controlled Outcome Trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of Liraglutide, a Glucagon-like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes ( LIVE )\u2014A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"19","author":"Jorsal","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of Once-Weekly Exenatide in Patients with Type 2 Diabetes Mellitus with and without Heart Failure and Heart Failure\u2013Related Outcomes","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Neves, J.S., Packer, M., and Ferreira, J.P. (2023). Increased Risk of Heart Failure Hospitalization with GLP-1 Receptor Agonists in Patients with Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials. J. Card. Failure.","DOI":"10.1016\/j.cardfail.2023.03.017"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.numecd.2021.06.002","article-title":"Cardiovascular Events and All-Cause Mortality in Patients with Type 2 Diabetes Treated with Dipeptidyl Peptidase-4 Inhibitors: An Extensive Meta-Analysis of Randomized Controlled Trials","volume":"31","author":"Mannucci","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues from Laboratory Models and Clinical Trials","volume":"122","author":"Packer","year":"2018","journal-title":"Circ. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Type 2 Diabetes: Systematic Review and Meta-analysis of Randomised and Observational Studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacasi.2022.09.015","article-title":"Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure with Preserved Ejection Fraction and Diabetes","volume":"3","author":"Enzan","year":"2023","journal-title":"JACC Asia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction","volume":"143","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: Results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/aca.aca_214_20","article-title":"Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery: A Preliminary Randomized-Controlled Trial","volume":"26","author":"Sindhvananda","year":"2023","journal-title":"Ann. Card. Anaesth."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/dom.13927","article-title":"Liraglutide for Perioperative Management of Hyperglycaemia in Cardiac Surgery Patients: A Multicentre Randomized Superiority Trial","volume":"22","author":"Hulst","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/dme.14084","article-title":"Addition of Low-Dose Liraglutide to Insulin Therapy Is Useful for Glycaemic Control during the Peri-Operative Period: Effect of Glucagon-like Peptide-1 Receptor Agonist Therapy on Glycaemic Control in Patients Undergoing Cardiac Surgery (GLOLIA Study)","volume":"36","author":"Makino","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1053\/j.jvca.2024.06.015","article-title":"Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Sub-Study of the Randomized Controlled GLOBE Trial","volume":"38","author":"Hermanides","year":"2024","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hulst, A.H., Visscher, M.J., Cherpanath, T.G.V., van de Wouw, L., Godfried, M.B., Thiel, B., Gerritse, B.M., Scohy, T.V., Bouwman, R.A., and Willemsen, M.G.A. (2020). Effects of Liraglutide on Myocardial Function after Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030673"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/dom.14241","article-title":"Sitagliptin for the Prevention and Treatment of Perioperative Hyperglycemia in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Randomized Controlled Trial","volume":"23","author":"Cardona","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sardu, C., Massetti, M., Testa, N., Di Martino, L., Castellano, G., Turriziani, F., Sasso, F.C., Torella, M., De Feo, M., and Santulli, G. (2021). Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients with Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.777083"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Al Namat, R., Duceac, L.D., Chelaru, L., Dabija, M.G., Gu\u021bu, C., Marcu, C., Popa, M.V., Popa, F., Goroftei, E.R.B., and \u021aarc\u0103, E. (2023). Post-Coronary Artery Bypass Grafting Outcomes of Patients with\/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14010016"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.ahjo.2022.100154","article-title":"Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus","volume":"18","author":"Cagliostro","year":"2022","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/aor.14733","article-title":"The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices","volume":"48","author":"Fardman","year":"2024","journal-title":"Artif. Organs"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/3\/427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:18Z","timestamp":1760028558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/3\/427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["life15030427"],"URL":"https:\/\/doi.org\/10.3390\/life15030427","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]}}}